TY - JOUR PY - 2001 DA - 2001// TI - Biomarkers and surrogate endpoints: preferred definitions and conceptual framework JO - Clin Pharmacol Ther VL - 69 UR - https://doi.org/10.1067/mcp.2001.113989 DO - 10.1067/mcp.2001.113989 ID - ref1 ER - TY - JOUR AU - Altar, C. A. PY - 2008 DA - 2008// TI - The biomarkers consortium: on the critical path of drug discovery JO - Clin Pharmacol Ther VL - 83 UR - https://doi.org/10.1038/sj.clpt.6100471 DO - 10.1038/sj.clpt.6100471 ID - Altar2008 ER - TY - JOUR AU - Hanahan, D. AU - Weinberg, R. PY - 2000 DA - 2000// TI - The hallmarks of cancer JO - Cell VL - 100 UR - https://doi.org/10.1016/S0092-8674(00)81683-9 DO - 10.1016/S0092-8674(00)81683-9 ID - Hanahan2000 ER - TY - JOUR AU - Newell, D. PY - 2003 DA - 2003// TI - The drug development process: from target discovery to the clinic JO - Clin Med VL - 3 UR - https://doi.org/10.7861/clinmedicine.3-4-323 DO - 10.7861/clinmedicine.3-4-323 ID - Newell2003 ER - TY - JOUR AU - Pepe, M. AU - Etzioni, R. AU - Feng, Z. AU - Potter, J. AU - Lou, M. PY - 2001 DA - 2001// TI - Phases of biomarkers development for early detection of cancer JO - J Natl Cancer Inst VL - 93 UR - https://doi.org/10.1093/jnci/93.14.1054 DO - 10.1093/jnci/93.14.1054 ID - Pepe2001 ER - TY - JOUR AU - Workman, P. AU - Aboagye, E. AU - Chung, Y. L. PY - 2006 DA - 2006// TI - Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies JO - J Natl Cancer Inst VL - 98 UR - https://doi.org/10.1093/jnci/djj162 DO - 10.1093/jnci/djj162 ID - Workman2006 ER - TY - JOUR AU - Wells, G. PY - 2009 DA - 2009// TI - Liver fibrosis: challenges of the new era JO - Gastroenterology VL - 136 UR - https://doi.org/10.1053/j.gastro.2008.12.028 DO - 10.1053/j.gastro.2008.12.028 ID - Wells2009 ER - TY - JOUR AU - Kelloff, G. AU - Sigman, C. PY - 2005 DA - 2005// TI - New science-based endpoints to accelerate oncology drug development JO - Eur J Cancer VL - 41 UR - https://doi.org/10.1016/j.ejca.2004.12.006 DO - 10.1016/j.ejca.2004.12.006 ID - Kelloff2005 ER - TY - JOUR AU - Carden, C. P. AU - Banerji, U. AU - Kaye, S. B. AU - Workman, P. AU - Bono, J. S. PY - 2009 DA - 2009// TI - From darkness to light with biomarkers in early clinical trials of cancer drugs JO - Clin Pharmacol Ther VL - 85 UR - https://doi.org/10.1038/clpt.2008.223 DO - 10.1038/clpt.2008.223 ID - Carden2009 ER - TY - JOUR AU - Ritcher, W. PY - 2006 DA - 2006// TI - Imaging biomarkers as surrogate endpoints for drug development JO - Eur J Nucl Med Mol Imaging VL - 33 ID - Ritcher2006 ER - TY - JOUR AU - Sargent, D. J. AU - Rubinstein, L. AU - Schwartz, L. PY - 2009 DA - 2009// TI - Validation of novel imaging methodologies for use as cancer clinical trial end-points JO - Eur J Cancer VL - 45 UR - https://doi.org/10.1016/j.ejca.2008.10.030 DO - 10.1016/j.ejca.2008.10.030 ID - Sargent2009 ER - TY - JOUR AU - Tofts, P. S. AU - Brix, G. AU - Buckley, D. L. PY - 1999 DA - 1999// TI - Estimating kinetic parameters from dynamic contrast enhanced T1-weighted MRI of a diffusable tracer: standardized quantities and symbols JO - J Magn Reson Imaging VL - 10 UR - https://doi.org/3.0.CO;2-S DO - 3.0.CO;2-S ID - Tofts1999 ER - TY - JOUR AU - Leach, M. O. AU - Brindle, K. M. AU - Evelhoch, J. L. PY - 2005 DA - 2005// TI - The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations JO - Brit J Cancer VL - 92 UR - https://doi.org/10.1038/sj.bjc.6602550 DO - 10.1038/sj.bjc.6602550 ID - Leach2005 ER - TY - JOUR AU - Padhani, A. R. AU - Liu, G. AU - Mu-Koh, D. PY - 2009 DA - 2009// TI - Diffusion weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations JO - Neoplasia VL - 11 UR - https://doi.org/10.1593/neo.81328 DO - 10.1593/neo.81328 ID - Padhani2009 ER - TY - JOUR AU - Beers, B. E. AU - Vilgrain, V. PY - 2009 DA - 2009// TI - Biomarkers in abdominal imaging JO - Abdom Imaging VL - 34 UR - https://doi.org/10.1007/s00261-008-9480-9 DO - 10.1007/s00261-008-9480-9 ID - Beers2009 ER - TY - JOUR AU - Buckler, A. J. AU - Mozley, P. D. AU - Schwartz, L. PY - 2010 DA - 2010// TI - Volumetric CT in lung cancer: an example for the qualification of imaging as a biomarker JO - Acad Radiol VL - 17 UR - https://doi.org/10.1016/j.acra.2009.06.019 DO - 10.1016/j.acra.2009.06.019 ID - Buckler2010 ER - TY - JOUR AU - Eisenhauser, E. A. AU - Therasse, P. AU - Bogaerts, J. PY - 2009 DA - 2009// TI - New response evaluation criteria in solid tumours: revised RECIST guideline (version 1) JO - Eur J Cancer VL - 45 UR - https://doi.org/10.1016/j.ejca.2008.10.026 DO - 10.1016/j.ejca.2008.10.026 ID - Eisenhauser2009 ER - TY - JOUR AU - Llovet, J. M. AU - Bisceglie, A. AU - Bruix, J. PY - 2008 DA - 2008// TI - Design and endpoints of clinical trials in hepatocellular carcinoma JO - J Natl Cancer Inst VL - 100 UR - https://doi.org/10.1093/jnci/djn134 DO - 10.1093/jnci/djn134 ID - Llovet2008 ER - TY - STD TI - European Medicines Agency (2007) Innovative drug development approaches. Final report from the EMEA/CHMP-Think-Tank group on innovative drug development. Doc.Ref.: EMEA/127318/2007 available at http://www.emea.europa.eu/pdfs/human/itf/12731807en.pdf UR - http://www.emea.europa.eu/pdfs/human/itf/12731807en.pdf ID - ref19 ER -